Imatinib Placebo

DRUG3 trials

Sponsors

Karolinska Institutet, Novartis Pharmaceuticals, Second Affiliated Hospital, School of Medicine, Zhejiang University

Conditions

Acute ischemic strokePalmoplantar Pustulosis (PPP)Rheumatoid Arthritis

Phase 2

A Study of Imatinib 400 mg Once Daily in Combination With Methotrexate in the Treatment of Rheumatoid Arthritis.

CompletedNCT00154336

Novartis PharmaceuticalsRheumatoid Arthritis

Start: 2004-07-31End: 2005-08-31Updated: 2017-04-25

Phase 3

A phase 3, randomised, double-blind, placebo-controlled, parallel-arm efficacy trial of Imatinib in acute ischaemic stroke

SuspendedCTIS2023-506178-11-00

Karolinska InstitutetAcute ischemic stroke

Start: 2025-11-11Target: 680Updated: 2023-11-07

A Phase III Randomized Controlled Trial Evaluating the Efficacy and Safety of Tofacitinib Combined With Imatinib in Patients With Moderate-to-Severe Palmoplantar Pustulosis

Not yet recruitingNCT07530367

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityPalmoplantar Pustulosis (PPP)

Start: 2026-04-01End: 2028-12-30Target: 135Updated: 2026-04-15